

## PRODUCT INFORMATION

<b>Target</b>	PD-L1
<b>Description</b>	Monoclonal Cell Line Derived from Jurkat Cells, Engineered for Stable Expression of Human PD-L1 Using Lentiviral Technology
<b>Host Cells</b>	Jurkat
<b>Uniprot ID</b>	Q9NZQ7
<b>Applications</b>	FACS Data
<b>Growth media</b>	RPMI-1640+10% FBS+1% P.S+1% Gln+2 ug/mL Puromycin
<b>Package</b>	5E6 Cells/mL
<b>Suggested Control</b>	SKU: BME100153
<b>Warranty and Disclaimer</b>	1. Please inspect cells upon receipt and report any issues promptly. 2. We offer one-time replacements for issues reported within a week of receipt. 3. User-induced issues are not eligible for free replacements. 4. We do not accept liability for damages resulting from cell use, storage, or loss. 5. Feedback received more than one month after receipt will not be processed.
<b>Storage &amp; Shipping</b>	Cells are shipped using dry ice and require liquid nitrogen storage for long term preservation.
<b>Synonyms</b>	PD-L1; CD274; B7-H1; PDCD1L1; PDCD1LG1
<b>Background</b>	This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells; such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue; this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments; this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies; including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.
<b>Usage</b>	For research use only.



## Hu\_PD-L1 Jurkat Cell Line




Figure 1. Flow cytometry analysis of human PD-L1 overexpression using Hu\_PD-L1 Jurkat Cell Line (Cat. No. CEL100023) and Anti-PDL1 (durvalumab biosimilar) mAb (Cat. No. BME100153)

